Drugs/Vaccines

Publications

click to view chapters and sections

Disease Control Priorities in Developing Countries (2nd Edition)

1. 25. Acute Respiratory Infections in Children
2. 33. Cardiovascular Disease
   1. Cost-Effectiveness of Interventions
3. 56. Community Health and Nutrition Programs
4. 69. Complementary and Alternative Medicine
   1. Economics of Complementary and Alternative Medicine and Traditional Medicine
   2. Lessons Learned and Implementation
5. 21. Conquering Malaria
   1. Economics of Malaria Control Interventions
   2. Interventions and Their Effectiveness
   3. Research Priorities
6. 15. Cost–Effectiveness Analysis for Priority Setting
7. 51. Cost–Effectiveness of Interventions for Musculoskeletal Conditions
   1. Treatments
8. 30. Diabetes: The Pandemic and Potential Solutions
   1. Cost-Effectiveness of Interventions and Priorities
9. 19. Diarrheal Diseases
   1. Case Management
10. 36. Diseases of the Kidney and the Urinary System
    1. Global Perspectives in Relation to RRT
11. 55. Drug Resistance
    1. Agenda for Action
    2. Conclusion
    3. Economic Burden
    4. Implementation of Strategies: Two Lessons from Experience
    5. Interventions
    6. Risk Factors
12. 7. Economic Approaches to Valuing Global Health Research
13. 72. Ensuring Supplies of Appropriate Drugs and Vaccines
    1. Adherence
    2. Conclusion
    3. Dispensing
    4. Drug Policies
    5. Financing Issues
    6. Issues for the Future
    7. Local Production of Pharmaceuticals
    8. Prescription and Rational Use of Drugs
    9. Priorities for Pharmaceutical Research
    10. Procurement of Drugs
    11. Procurement of Vaccines
    12. Quality Assurance for Pharmaceuticals and Vaccines
    13. Selection of Drugs
    14. Selection of Vaccines
    15. Storage and Distribution of Essential Drugs and Vaccines
    16. Sustainable Financing of Vaccines and Immunizations
    17. The WHO Prequalification Schemes
    18. Vaccine Policies
    19. Vaccine Research Priorities
14. 14. Ethical Issues in Resource Allocation, Research, and New Product Development
    1. Ethics in Research and New Product Development
15. 12. Financing Health Systems in the 21st Century
16. 11. Fiscal Policies for Health Promotion and Disease Prevention
17. 10. Gender Differentials in Health
18. 64. General Primary Care
19. 29. Health Service Interventions for Cancer Control in Developing Countries
    1. Applicability of Cost-Effectiveness Studies from Developed to Developing Countries
20. 71. Health Workers: Building and Motivating the Workforce
21. 24. Helminth Infections: Soil–Transmitted Helminth Infections and Schistosomiasis
    1. Cost-Effectiveness Analysis of Interventions
    2. Research and Development
22. 18. HIV/AIDS Prevention and Treatment
    1. Action under Uncertainty
    2. Care and Treatment
    3. Prevention in Theory and Practice: Using Epidemic Profiles and Contextual Factors to Inform Prevention Guidelines
    4. Research Agenda
23. 48. Illicit Opiate Abuse
    1. Annex 48.A: Prevalence of Use, Adverse Health Effects of and Interventions for Cannabis, Cocaine, Amphetamines, and MDMA Use and Dependence
    2. Conclusions: Promises and Pitfalls
    3. Interventions for Illicit Opioid Dependence
    4. Nature, Causes, and Health Consequences of Illicit Opioid Use
    5. Relevance to Developing Countries
24. 8. Improving the Health of Populations: Lessons of Experience
    1. Intervention Type, Programmatic Characteristics, and Policies
25. 34. Inherited Disorders of Hemoglobin
26. 63. Integrated Management of the Sick Child
    1. Implementation of Programs: Lessons of Experience
    2. Intervention Cost and Cost-Effectiveness
27. 2. Intervention Cost–Effectiveness: Overview of Main Messages
    1. Assessing the Evidence on the Cost-Effectiveness of Interventions
28. 1. Investing in Health
    1. Conclusions
    2. HIV/AIDS
    3. Noncommunicable Disease and Injury
29. 49. Learning and Developmental Disabilities
30. 26. Maternal and Perinatal Conditions
31. 31. Mental Disorders
    1. Cost-Effectiveness Methods and Results
    2. Mood Disorders
    3. Schizophrenia and Nonaffective Psychoses
32. 9. Millennium Development Goals for Health: What Will It Take to Accelerate Progress?
33. 32. Neurological Disorders
34. 27. Newborn Survival
35. 38. Oral and Craniofacial Diseases and Disorders
36. 52. Pain Control for People with Cancer and AIDS
    1. Costs and Cost-Effectiveness
    2. Interventions for Pain Relief
37. 44. Prevention of Chronic Disease by Means of Diet and Lifestyle Changes
38. 4. Priorities for Global Research and Development of Interventions
    1. Needs, Context, Opportunities, and Major Challenges
    2. Priority Setting
39. 6. Product Development Priorities
    1. Financing and Institutional Arrangements for New Product Development
    2. Intellectual Property
    3. Introduction
    4. Pharmaceutical Products
40. 53. Public Health Surveillance: A Tool for Targeting and Monitoring Intervention
41. 13. Recent Trends and Innovations in Development Assistance for Health
42. 35. Respiratory Diseases of Adults
    1. Chronic Respiratory Diseases: Nature, Causes, and Burden
43. 5. Science and Technology for Disease Control: Past, Present, and Future
    1. Science, Technology, and Medicine in the 20th Century
    2. Science, Technology, and Medicine in the Future
44. 17. Sexually Transmitted Infections
    1. Bacterial and Viral STIs and Their Sequelae
    2. Introduction
45. 37. Skin Diseases
    1. Skin Diseases
46. 73. Strategic Management of Clinical Services
    1. The Specifics: What Works?
47. 3. Strengthening Health Systems
    1. Targeting Resources
48. 28. Stunting, Wasting, and Micronutrient Deficiency Disorders
49. 67. Surgery
50. 45. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight
    1. Cost-Effectiveness of Interventions
    2. Interventions
51. 23. Tropical Diseases Lacking Adequate Control Measures: Dengue, Leishmaniasis, and African Trypanosomiasis
    1. Costs and Cost-Effectiveness of Interventions
    2. Disease Burden
    3. Problems and Challenges for Disease Control
52. 22. Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy
    1. Interventions and Their Effectiveness
53. 16. Tuberculosis
    1. Alternative and Complementary Approaches to the Diagnosis and Treatment of Active Disease
    2. Cost-Effectiveness of Interventions against Tuberculosis
    3. Cost-Effectiveness of Managing Tuberculosis Outbreaks
    4. Interventions against Tuberculosis
    5. Research and Development

Global Burden of Disease and Risk Factors

1. 4. Comparative Quantification of Mortality and Burden of Disease Attributable to Selected Risk Factors
2. 3. The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001
   1. Estimating Deaths by Cause: Methods and Data
   2. Estimating Incidence, Prevalence, and YLD: Methods and Data

Priorities in Health

1. 1. Accomplishments, Challenges, and Priorities
2. 5. Cost–Effective Strategies for Noncommunicable Diseases, Risk Factors, and Behaviors
   1. Mental Health
3. 4. Cost–Effective Strategies for the Excess Burden of Disease in Developing Countries
   1. Infectious and Communicable Diseases
4. 3. Cost–Effectiveness Analysis
5. 7. Pillars of the Health System
6. 6. Providing Interventions
   1. Cross-Level Services and Inputs
7. 2. Success in Addressing Priorities